Published in Oncotarget on March 15, 2016
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | NCT01449461
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | NCT01579994
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | NCT01772797
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med (2016) 1.38
Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res (2016) 0.85
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer (2009) 6.74
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A (2008) 4.45
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov (2014) 3.31
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature (2014) 3.15
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One (2011) 3.10
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene (1997) 2.80
ALK in lung cancer: past, present, and future. J Clin Oncol (2013) 2.70
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer (2003) 2.67
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol (2014) 2.42
Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 2.11
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta (2008) 1.77
Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci U S A (1990) 1.73
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem (2001) 1.71
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer (2014) 1.65
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell (2015) 1.62
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem (2002) 1.58
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer (2007) 1.53
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol (2014) 1.48
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev (2013) 1.43
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res (2012) 1.42
The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev (1996) 1.39
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol (2011) 1.31
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther (2012) 1.21
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A (2013) 1.19
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 1.17
Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther (2011) 1.17
Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev (2014) 1.10
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res (2015) 1.07
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res (2014) 1.02
ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev (2010) 1.01
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. J Clin Oncol (2014) 1.01
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res (2013) 1.00
Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol (2013) 1.00
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A (2015) 0.97
Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer (2014) 0.97
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer (2013) 0.95
P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. PLoS Comput Biol (2014) 0.95
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res (2015) 0.94
Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood (1995) 0.94
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs (2013) 0.93
ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer (2013) 0.92
EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics (2013) 0.90
Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood (1997) 0.88
A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. Biochem Biophys Res Commun (2012) 0.88
Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. Eur J Cancer (2013) 0.88
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget (2015) 0.87
ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst (2012) 0.84
Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget (2015) 0.83
High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. Br J Cancer (2013) 0.83
Treatment and detection of ALK-rearranged NSCLC. Lung Cancer (2013) 0.82
ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res (2013) 0.81
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. J Mol Model (2015) 0.81
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther (2015) 0.78
Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer. Lung Cancer (2014) 0.75
Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res (2017) 0.75
Up-regulated basigin-2 in microglia induced by hypoxia promotes retinal angiogenesis. J Cell Mol Med (2017) 0.75